Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439750 | 1.00 | PLAU (0.51) | PLAUPLGPLATLMNACYP3A4 | |
| SCHEMBL1536295 | 0.84 | PLAU (0.51) | PLAUPLGPLATLMNACYP3A4 | |
| SCHEMBL30111349 | 0.84 | PLAU (0.51) | PLAUPLGPLATLMNACYP3A4 | |
| SCHEMBL1317870 | 0.79 | LMNA (0.50) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL29786977 | 0.79 | LMNA (0.50) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL25368878 | 0.76 | MAPT (0.47) | PLAULMNACYP3A4MAPTAPEX1 | |
| SCHEMBL1243375 | 0.76 | CYP3A4 (0.47) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL664591 | 0.76 | LMNA (0.47) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL30497190 | 0.76 | LMNA (0.47) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL13334192 | 0.76 | LMNA (0.47) | PLAUPLGPLATLMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125357-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | GLIAPHARM SA (CH) | 2026-05-07 | — | — | US | disclosed |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| CN-120035439-A | Lactic acid enhancing compounds and uses thereof | 格莱制药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119504706-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2025-02-25 | — | — | CN | disclosed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| WO-2001012600-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| CN-1275979-A | Isoquinoline compounds useful as urokinase inhibitors | PFIZER (US) | 2000-12-06 | — | — | CN | disclosed |
| WO-2000071512-A1 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000047554-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | PLAU 2528/4885PLG 1785/4885PLAT 2502/4885 |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | PLAU 4124/4885PLG 4628/4885PLAT 4463/4885 |
| US-20260125357-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | LDHA, PC, LDHB | PLAU 3557/4885PLG 2191/4885PLAT 4103/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | PLAU 4733/4885PLG 4478/4885PLAT 4831/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PLAU 1220/4885PLG 1249/4885PLAT 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.